157 related articles for article (PubMed ID: 24914044)
1. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
Boku N; Muro K; Machida N; Hashigaki S; Kimura N; Suzuki M; Lechuga M; Miyata Y
Invest New Drugs; 2014 Apr; 32(2):261-70. PubMed ID: 23665950
[TBL] [Abstract][Full Text] [Related]
7. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes G; Wilding G; Schwartz LH; Hariharan S; Kempin S; Fayyad R; Figlin RA
Clin Genitourin Cancer; 2009 Jan; 7(1):28-33. PubMed ID: 19213665
[TBL] [Abstract][Full Text] [Related]
9. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
11. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Shinohara N; Yuasa T; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Uemura H; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Dec; 40(12):1166-72. PubMed ID: 20713418
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
Campbell MT; Millikan RE; Altinmakas E; Xiao L; Wen SJ; Siefker-Radtke AO; Aparicio A; Corn PG; Tannir NM
Clin Genitourin Cancer; 2015 Jun; 13(3):218-24. PubMed ID: 25465491
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
16. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ
Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
[TBL] [Abstract][Full Text] [Related]
20. A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
Kanesvaran R; Watt K; Turnbull JD; Armstrong AJ; Wolkowiez MC; George DJ
Clin Genitourin Cancer; 2015 Aug; 13(4):319-327. PubMed ID: 26174223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
